MCF Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

MCF Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1,073	Closed	-$5.16K	–	1027
2026 Q2	$5.16K	Buy	+1,073	New	+$4.27K	﹤0.01%	1153

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Ritholtz Wealth Management New York $6.96B AUM 24% 1-Year Est. Return

Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

SCM

Sage Capital Management Stockton, New Jersey $263M AUM 22.29% 1-Year Est. Return

MCF Advisors's ORMP Position: Q3 2026 in Review

MCF Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q3 2026, closing a stake of 1,073 shares — an estimated $5.16K sold.

MCF Advisors first reported a position in ORMP in Q2 2026 and held it in 1 quarter. The position peaked at $5.16K in Q2 2026. 29 funds tracked by Wall St. Rank hold ORMP as of Q3 2026.

MCF Advisors reported no remaining Oramed Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
MCF Advisors sold 1,073 Oramed Pharmaceuticals shares in Q3 2026, an estimated $5.16K.
MCF Advisors first reported a position in Oramed Pharmaceuticals in Q2 2026 and held it in 1 quarter.
MCF Advisors's Oramed Pharmaceuticals position peaked at $5.16K in Q2 2026.
29 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2026.

Based on MCF Advisors's 13F filing for Q3 2026, filed 28 Oct 2026.